New therapeutic options for onychomycosis

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 8, 2012, Pages 1131-1142

  Gupta, Aditya K ^a   Simpson, Fiona C ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

Author keywords

Allylamine; Azole; Benzoxaborole; Dermatophyte; Iontophoresis; Laser; Mold; Onychomycosis; Photodynamic therapy; Yeast

Indexed keywords

ALBACONAZOLE; AMINOLEVULINIC ACID; AMOROLFINE; AMPHOTERICIN B; AN 2718; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BIFONAZOLE; BUTENAFINE; CASPOFUNGIN; CICLOPIROX; EFINACONAZOLE; GRISEOFULVIN; ITRACONAZOLE; LULICONAZOLE; MICAFUNGIN; NAFTIFINE; NB 002; POLYMER; POSACONAZOLE; PRAMICONAZOLE; RAVUCONAZOLE; TAVABOROLE; TDT 067; TERBINAFINE; TOLNAFTATE; UNCLASSIFIED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; APPLICATION SITE PRURITUS; BACKACHE; BURNING SENSATION; DIARRHEA; DIODE LASER; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FATIGUE; FUNGICIDAL ACTIVITY; HAIR GROWTH; HEADACHE; HEALING; HUMAN; INFLUENZA; IONTOPHORESIS; LASER; NAUSEA; NEODYMIUM LASER; NONHUMAN; ONYCHOMYCOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; REVIEW; RHINOPHARYNGITIS; SKIN DEFECT; TITANIUM SAPPHIRE LASER;

ALLYLAMINE; ANTIFUNGAL AGENTS; AZOLES; BICYCLO COMPOUNDS, HETEROCYCLIC; BORON COMPOUNDS; ECHINOCANDINS; HUMANS; IONTOPHORESIS; LASERS; NAPHTHALENES; ONYCHOMYCOSIS; PHOTOCHEMOTHERAPY; POLYMERS;

EID: 84861327425     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.681779     Document Type: Review

References (99)

1. Burzykowski T, Molenberghs G, Abeck D, et al. High prevalence of foot diseases in Europe: results of the Achilles project. Mycoses 2003;46 (11-12): 496-505 (Pubitemid 38005347)
2. Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000;43 (4): 641-8
3. Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians a offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 2000;43 (2): 244-8 (Pubitemid 30626001)
4. Pierard G. Onychomycosis and other superficial fungal infections of the foot in the elderly: a pan-European survey. Dermatology 2001;202 (3): 220-4 (Pubitemid 32506969)
5. Reich A, Szepietowski JC. Health-related quality of life in patients with nail disorders. Am J Clin Dermatol 2011;12 (5): 313-20
6. Baran R. The nail in the elderly. Clin Dermatol 2011;29 (1): 54-60
7. Gupta AK, Humke S. The prevalence and management of onychomycosis in diabetic patients. Eur J Dermatol 2000;10 (5): 379-84
8. Gupta AK, Gupta MA, Summerbell RC, et al. The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. J Eur Acad Dermatol Venereol 2000;14 (6): 466-9 (Pubitemid 32899268)
9. Gruseck E, Abeck D, Ring J. Relapsing severe trichophyton rubrum infections in an immunocompromised host: evidence of onychomycosis as a source of reinfection based on lectin typing. Mycoses 1993;36 (7-8): 275-8 (Pubitemid 23355095)
10. Gupta AK, Taborda P, Taborda V, et al. Epidemiology and prevalence of onychomycosis in HIV-positive individuals. Int J Dermatol 2000;39 (10): 746-53
11. Doner N, Yasar S, Ekmekci TR. Evaluation of obesity-associated dermatoses in obese and overweight individuals. Turkderm 2011;45 (3): 146-51
12. Baran R, Gupta AK, Pierard GE. Pharmacotherapy of onychomycosis. Expert Opinion on Pharmacotherapy 2005;6 (4): 609-24 (Pubitemid 40613888)
13. Murdan S. 1st meeting on topical drug delivery to the nail. Expert Opin Drug Deliv 2007;4 (4): 453-5 (Pubitemid 47249142)
14. Piraccini BM, Sisti A, Tosti A. Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. J Am Acad Dermatol 2010;62 (3): 411-14
15. Scher RK, Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol 2003;149 (Suppl 65): 5-9 (Pubitemid 37410064)
16. Shear N, Drake L, Gupta AK, et al. The implications and management of drug interactions with itraconazole, fluconazole and terbinafine. Dermatology 2000;201 (3): 196-203
17. Krishnan-Natesan S. Terbinafine: a pharmacological and clinical review. Expert Opinion on Pharmacotherapy 2009;10 (16): 2723-33
18. Novartis. Lamisil Product Label. 2011.Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/020539s018lbl.pdf
19. Ghannoum MA, Long L, Pfister WR. Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of dermatophytosis in a guinea pig model. Mycoses 2009;52 (1): 35-43
20. Elewski BE, Ghannoum MA, Mayser P, et al. Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs J Eur Acad Dermatol Venereol 2011. [Epub ahead of print]
21. Ghannoum M, Isham N, Herbert J, et al. Activity of TDT 067 (terbinafine in Transfersome) against agents of onychomycosis, as determined by minimum inhibitory and fungicidal concentrations. J Clin Microbiol 2011;49 (5): 1716-20
22. Dominicus R, Weidner C, Tate H, et al. Open-label study of the efficacy and safety of topical treatment with TDT 067 (terbinafine in Transfersome (R)) in patients with onychomycosis. Br J Dermatol 2011. [Epub ahead of print]
23. Pannu J, McCarthy A, Martin A, et al. NB-002, a novel nanoemulsion with broad antifungal activity against dermatophytes, other filamentous fungi, and Candida albicans. Antimicrob Agents Chemother 2009;53 (8): 3273-9
24. ClinicalTrials.gov. Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail. Available from: http:// clinicaltrials.gov/ct2/ show/NCT00453271 [Cited 21 December 2011]
25. Girmenia C. New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs 2009;18 (9): 1279-95
26. Schering. Noxafil Product Label. Available from: http://www.accessdata. fda.gov/drugsatfda-docs/label/2010/022003s008,022027s001lbl.pdf [Cited12 December 2011]
27. Elewski B, Pollak R, Ashton S, et al. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol 2011; [Epub ahead of print]
28. Gupta AK, Leonardi C, Stoltz RR, et al. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol Venereol 2005;19 (4): 437-43 (Pubitemid 40946096)
29. Pfizer. VFEND Product Label. Available from: http://www.accessdata.fda. gov/drugsatfda-docs/label/2011/021266s035,021267s040,021630s026lbl.pdf [Cited 12 December 2011]
30. Carrillo-Munoz AJ, Giusiano G, Guarro J, et al. In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis. Int J Antimicrob Agents 2007;30 (2): 157-61 (Pubitemid 46977191)
31. ClinicalTrials.gov. A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received aSingle Dose of 400 mg Albaconazole as aTablet Versus Albaconazole as a Capsule. 2010.Available from: http://clinicaltrials.gov/ct2/show/NCT01039883 [Cited12 December 2011]
32. ClinicalTrials.gov. Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis. Available from: http://clinicaltrials.gov/ct2/show/ NCT00730405 [Cited 12 December 2011]
33. Bartroli J, Turmo E, Alguero M, et al. New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4 (3H)-quinazolinones. J Med Chem 1998;41 (11): 1869-82 (Pubitemid 28248662)
34. Ramos G, Cuenca-Estrella M, Monzon A, et al. In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. J Antimicrob Chemother 1999;44 (2): 283-6 (Pubitemid 29389293)
35. Schaller M, Borelli C, Berger U, et al. Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection. Med Mycol 2009;47 (7): 753-8
36. ClinicalTrials.gov.comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste. Available from: http://clinicaltrials.gov/ ct2/show/NCT00781820 [Cited 13 December 2011]
37. ClinicalTrials.gov. The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis. Available from: http://clinicaltrials. gov/ct2/show/NCT01007708 [Cited 13 December 2011]
38. Fernandez-Torres B, Inza I, Guarro J. Evaluation of disk diffusion method for determining eberconazole susceptibility of dermatophytes and influence of culture medium. Antimicrob Agents Chemother 2005;49 (5): 2116-18 (Pubitemid 40631635)
39. Fernandez-Torres B, Inza I, Guarro J. In vitro activities of the new antifungal drug eberconazole and three other topical agents against 200 strains of dermatophytes. J Clin Microbiol 2003;41 (11): 5209-11 (Pubitemid 37429942)
40. ClinicalTrials.gov. Open-Label Pharmacokinetics (PK)/Safety Study of Luliconazole Solution, 10% in Distal Subungual Onychomycosis. Available from: http://clinicaltrials.gov/ct2/show/NCT01044381 [Cited 12 December 2011]
41. ClinicalTrials.gov. Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis (SOLUTION). Available from: http://clinicaltrials.gov/ct2/show/NCT01431820[Cited 12 December 2011]
42. Ghannoum MA, Long L, Kim HG, et al. Efficacy of terbinafine compared to lanoconazole and luliconazole in the topical treatment of dermatophytosis in aguinea pig model. Med Mycol 48 (3): 491-7
43. Koga H, Nanjoh Y, Makimura K, et al. In vitro antifungal activities of luliconazole, a new topical imidazole. Med Mycol 2009;47 (6): 640-7
44. Koga H, Tsuji Y, Inoue K, et al. In vitro antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses. J Infect Chemother 2006;12 (3): 163-5 (Pubitemid 44025022)
45. Topica Pharmaceuticals. Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis (SOLUTION). 2011.Available from: http://clinicaltrials.gov/ct2/show/NCT01431820
46. Uchida K, Nishiyama Y, Yamaguchi H. In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent. J Infect Chemother 2004;10 (4): 216-19 (Pubitemid 39273440)
47. Vanden Bossche H, Ausma J, Bohets H, et al. The novel azole R126638 is aselective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp, and Microsporum canis. Antimicrob Agents Chemother 2004;48 (9): 3272-8 (Pubitemid 39129318)
48. Odds F, Ausma J, Van Gerven F, et al. In vitro and in vivo activities of the novel azole antifungal agent r126638. Antimicrob Agents Chemother 2004;48 (2): 388-91 (Pubitemid 38141692)
49. Baker SJ, Zhang YK, Akama T, et al. Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1- hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem 2006;49 (15): 4447-50 (Pubitemid 44162669)
50. Rock FL, Mao W, Yaremchuk A, et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 2007;316 (5832): 1759-61 (Pubitemid 46988553)
51. Hui X, Baker SJ, Wester RC, et al. In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J Pharm Sci 2007;96 (10): 2622-31 (Pubitemid 47597813)
52. Benter K, Toledo-Bahena M, Barbosa-Alanis H, et al. Interim Results of a Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solutions for the Treatment of Onychomycosis of the Great Toenail. J Am Acad Dermatol 2009;60 (3 Suppl): AB116
53. ClinicalTrials.gov. Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail. Available from: http://clinicaltrials.gov/ct2/show/NCT01270971 [Cited 14 December 2011]
54. ClinicalTrials.gov. Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail. Available from: http://clinicaltrials.gov/ ct2/show/NCT01302119 [Cited 14 December 2011]
55. Mao W, Seiradake E, Crepin T, et al. AN2718 has Broad Spectrum Antifungal Activity Necessary for the Topical Treatment of Skin and Nail Fungal Infections. J Am Acad Dermatol 2007: 56 (2 Suppl): AB124
56. ClinicalTrials.gov. Cumulative Irritation Test. Available from: http://clinicaltrials.gov/ct2/show/NCT00781664 [Cited 11 December 2011]
57. Pound MW, Townsend ML, Dimondi V, et al. Overview of treatment options for invasive fungal infections. Med Mycol 2011;49 (6): 561-80
58. Astellas. Mycamine Product label. Available from: http://www.accessdata. fda.gov/drugsatfda-docs/label/2011/021506s011s012lbl.pdf [Cited16 December 2011]
59. Merck & Co, Inc. Candicas Product Label. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/021227s028lbl.pdf [Cited16 December 2011]
60. Pfizer. Eraxis Product Label. Available from: http://www.accessdata.fda. gov/drugsatfda-docs/label/2006/021632s000,021948s000lbl.pdf [Cited 16 December 2011]
61. Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacother 2009;43 (10): 1647-57
62. Nasir A, Goldstein B, van Cleeff M, et al. Clinical evaluation of safety and efficacy of a new topical treatment for onychomycosis. J Drugs Dermatol 2011;10 (10): 1186-91
63. Gilaberte Y, Aspiroz C, Martes MP, et al. Treatment of refractory fingernail onychomycosis caused by nondermatophyte molds with methylaminolevulinate photodynamic therapy. J Am Acad Dermatol 2010;65 (3): 669-71
64. Piraccini BM, Rech G, Tosti A. Photodynamic therapy of onychomycosis caused by trichophyton rubrum. J Am Acad Dermatol 2008;59 (5 Suppl): S75-6
65. Sotiriou E, Koussidou-Eremonti T, Chaidemenos G, et al. Photodynamic therapy for distal and lateral subungual toenail onychomycosis caused by trichophyton rubrum: preliminary results of a single-centre open trial. Acta Derm Venereol 2010;90 (2): 216-17
66. Watanabe D, Kawamura C, Masuda Y, et al. Successful treatment of toenail onychomycosis with photodynamic therapy. Arch Dermatol 2008;144 (1): 19-21 (Pubitemid 351159403)
67. Harris F, Pierpoint L. Photodynamic therapy based on 5-aminolevulinic acid and its use as an antimicrobial agent. Med Res Rev 2011. [Epub ahead of print]
68. Smijs TG, Schuitmaker HJ. Photodynamic inactivation of the dermatophyte Trichophyton rubrum. Photochem Photobiol 2003;77 (5): 556-60
69. Smijs TG, van der Haas RN, Lugtenburg J, et al. Photodynamic treatment of the dermatophyte Trichophyton rubrum and its microconidia with porphyrin photosensitizers. Photochem Photobiol 2004;80 (2): 197-202
70. Smijs TG, Bouwstra JA, Talebi M, et al. Investigation of conditions involved in the susceptibility of the dermatophyte Trichophyton rubrum to photodynamic treatment. J Antimicrob Chemother 2007;60 (4): 750-9 (Pubitemid 47434252)
71. Smijs TG, Bouwstra JA, Schuitmaker HJ, et al. A novel ex vivo skin model to study the susceptibility of the dermatophyte Trichophyton rubrum to photodynamic treatment in different growth phases. J Antimicrob Chemother 2007;59 (3): 433-40 (Pubitemid 47073448)
72. Smijs TG, Mulder AA, Pavel S, et al. Morphological changes of the dermatophyte Trichophyton rubrum after photodynamic treatment: a scanning electron microscopy study. Med Mycol 2008;46 (4): 315-25 (Pubitemid 351552486)
73. Smijs TG, Pavel S, Talebi M, et al. Preclinical studies with 5,10,15-Tris (4- methylpyridinium)-20-phenyl- [21H,23H]-porphine trichloride for the photodynamic treatment of superficial mycoses caused by Trichophyton rubrum. Photochem Photobiol 2009;85 (3): 733-9
74. Smijs TG, Pavel S. The susceptibility of dermatophytes to photodynamic treatment with special focus on trichophyton rubrum. Photochem Photobiol 2011;87 (1): 2-13
75. ClinicalTrials.gov. Available from: http:// clinicaltrials.gov/ct2/ results? term=onychomycosis+photodynamic+therapy [Cited 19 December 2011]
76. Amichai B, Nitzan B, Mosckovitz R, et al. Iontophoretic delivery of terbinafine in onychomycosis: a preliminary study. Br J Dermatol 2009;162 (1): 46-50
77. Transport Pharmaceuticals. Iontophoretic Application of Terbinafine Gel to the Large Toe Nail. 2009.Available from: http://clinicaltrials.gov/ct2/show/ NCT00768768 [Cited 9 November 2011]
78. Nitric BioTherapeutics, Inc. Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail. Available from: http://clinicaltrials.gov/ct2/show/NCT01484145 [Cited 5 January 2012]
79. Kozarev J. Summary: clearsteps - laser onychomycosis treatment: assessment of efficacy 12 months after treatment and beyond. J Laser Health Acad 2011;2011 (1): S07
80. Kozarev J, Vizintin Z. Novel laser therapy in treatment of onychomycosis. J Laser Health Acad 2010;1: 1-8
81. FDA 510 (k) Summary K111483. Joule ClearSense, Sciton, Inc. 2011.Available from: http://www.accessdata.fda.gov/cdrh-docs/pdf11/K111483.pdf
82. FDA 510 (k) Summary K093547. PinPointe FootLaser, PinPointe USA, Inc. 2010.Available from: http://www.accessdata.fda.gov/cdrh-docs/pdf9/K093547.pdf
83. Harris DM, McDowell BA, Stristower J. Laser treatment for toenail fungus. Proc SPIE 2009;71610 (M): 1-7
84. FDA 510 (k) Summary K103626. Cutera GenesisPlus Laser System, Cutera, Inc. 2010.Available from: http://www.accessdata.fda.gov/cdrh-docs/pdf10/K103626. pdf
85. Weiss D. 3 Month Clinical Results using Sub-Millisecond 1064 nm Nd: YAG Laser for the Treatment of Onychomycosis. 2011. Available from: http://www.weissfootandankle.com/resources/White%20Paper-Dr%z20Weiss.pdf [Cited 21December 2011]
86. CoolTouch, Inc. CoolBreeze Features. 2011.Available from: http://www.cooltouch.com/CoolBreeze-laser-features.aspx [Cited 23 December 2011]
87. CoolTouch, Inc. CoolTouch CT3Plus Laser Specifications. 2011.Available from: http://www.cooltouch.com/CT3Plus-specifications.aspx [Cited 23 December 2011]
88. FDA 510 (k) Summary K110370. Q-Clear, Light Age, Inc. 2011.Available from: http://www.accessdata.fda.gov/cdrh-docs/pdf11/K110370.pdf [Cited 24 October 2011]
89. Bornstein E. A review of current research in light-based technologies for treatment of podiatric infectious disease states. JAm Podiatr Med Assoc 2009.99 (4): 348-52
90. Bornstein E, Hermans W, Gridley S, et al. Near-infrared photoinactivation of bacteria and fungi at physiologic temperatures. Photochem Photobiol 2009;85 (6): 1364-74
91. Landsman AS, Robbins AH, Angelini PF, et al. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure. J Am Podiatr Med Assoc 2010;100 (3): 166-77
92. ClinicalTrials.gov. Diode Laser Treatment of Onychomycosis. 2011.Available from: http://clinicaltrials. gov/ct2/show/NCT01452490 [Cited 9 November 2011]
93. Vural E, Winfield HL, Shingleton AW, et al. The effects of laser irradiation on trichophyton rubrum growth. Lasers Med Sci 2008;23 (4): 349-53
94. Hochman LG. Laser treatment of onychomycosis using a novel 0.65- millisecond pulsed Nd: YAG 1064-nm laser. J Cosmet Laser Ther 2011;13 (1): 2-5
95. Waibel J. Introducing the Sciton ClearSense Accessory featuring the ClearToe treatment for Onychomycosis (For Non-U.S. Customers). 2011.Available from: http://www.sciton.com/node/2388 [Cited 12 January 2012]
96. University of California, Irvine. 1320 nm Nd: YAG Laser for Improving the Appearance of Onychomycosis. 2011.Available from: http://clinicaltrials.gov/ ct2/show/NCT01498393 [Cited23 December 2011]
97. Manevitch Z, Lev D, Hochberg M, et al. Direct antifungal effect of femtosecond laser on trichophyton rubrum onychomycosis. Photochem Photobiol 2010.86 (2): 476-9
98. Nomir Medical Technologies. Using Light Therapy to Treat Toe Nail Fungus. 2008.Available from: http://clinicaltrials.gov/ct2/show/NCT00771732 [Cited 9 November 2011]
99. Nomir Medical Technologies. Treating Onychomychosis. 2008.Available from: http://clinicaltrials.gov/ct2/show/NCT00776464 [Cited 9 November 2011]